Familial (ATTR) amyloidosis misdiagnosed as the primary (AL) variant: a case report by Dattilo, Philip B
BioMed  Central
Page 1 of 4
(page number not for citation purposes)
Cases Journal
Open Access Case Report
Familial (ATTR) amyloidosis misdiagnosed as the primary (AL) 
variant: a case report
Philip B Dattilo
Address: Division of Cardiology, University of Colorado, Denver, Denver, CO, USA
Email: Philip B Dattilo - phil.dattilo@gmail.com
Abstract
Introduction: Primary (AL) Amyloidosis is arguably the most recognizable variant of the disease
with many classic signs. However, it has been argued that the Familial variant (ATTR) is actually
more prevalent. It is less recognizable, however, as its spectrum of organ involvement is frequently
much more limited. The two variants carry significantly different prognoses, have divergent
treatment strategies, and very different implications for the family members of patients. There is
now a small amount of data that would suggest Familial Amyloidosis may be misdiagnosed as the
AL form 2-4% of the time as a result of laboratory error.
Case presentation: Herein a case of Familial Amyloidosis initially mistaken for the AL form based
on a false positive laboratory result is presented. This case illustrates the high index of suspicion
required for proper diagnosis of this rare disease.
Conclusion: Clinician awareness of the various forms of Amyloidosis and the potential for lab
error is key to ensuring an accurate diagnosis. The two most common forms carry significantly
different implications for treatment and for potential impact on relatives. A high index of suspicion
is required particularly for the Familial form of Amyloidosis.
Introduction
Familial (ATTR) Amyloidosis is possibly the most com-
mon form of a rare disease, a result of mutant transthyre-
tin deposition in the affected organs [1]. A specific variant
of the transthyretin protein - Ile 122 - has been implicated
as a cause of cardiac amyloidosis in those of African herit-
age [2]. It is believed to play a role in the increased rate of
isolated cardiac amyloidosis seen in American Blacks after
the age of 60. Isolated cardiac amyloidosis due to Primary
(AL) Amyloidosis is relatively uncommon in general [1],
and specifically in non-Caucasian populations [3-5]. Case
series have described AL amyloidosis as being more prev-
alent in males and as occurring at a younger age than tran-
sthyretin-related amyloidosis [6,7]. AL amyloidosis
commonly involves multiple organ systems, and not
infrequently causes the nephrotic syndrome, the carpal
tunnel syndrome, hepatomegaly, and macroglossia [6-8].
While ATTR amyloidosis may be more prevalent than AL,
it is arguably less recognizable and therefore harder to
diagnose, as it not infrequently presents simply as hyper-
trophic heart failure [1]. Given the difference in prognosis
(ATTR carries a less rapidly lethal outcome), and the fact
that ATTR is hereditary and potentially treatable if caught
at an early stage by liver transplant [9] or possibly phar-
macologically [10], it is important to differentiate these
two types of amyloidosis.
The case below describes a case of ATTR Amyloidosis mis-
diagnosed as AL initially, based on a falsely positive stain
for light chain deposition.
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Case presentation
A 75 year old Jamaican Female of African descent was
admitted for shortness of breath. She had been complain-
ing of fatigue and shortness of breath for six months since
arriving in the U.S. from Jamaica. She reported mild
symptoms in Jamaica, but felt they had worsened during
her time in the States. She had been admitted multiple
times to at least four different hospitals since her symp-
toms began. She had been treated for both congestive
heart failure (CHF) and asthma exacerbations, despite car-
rying no significant history of either condition. At the time
of the admission described herein, she had been dis-
charged from another hospital two days prior on a tapered
prednisone regimen prescribed for an "asthma exacerba-
tion".
A review of systems at the time of admission revealed
symptoms consistent with New York Heart Association
Class IV CHF, including orthopnea, paroxysmal nocturnal
dyspnea, lower extremity edema, and a virtually non-
existent exercise tolerance.
On examination the patient was in acute distress, sitting
bolt upright in bed and tripodding. She was obese. Jugular
venous distension was difficult to discern due to her body
habitus. She did not have a palpable point of maximal
impulse. Her heart sounds were distant but regular with a
II/VI systolic ejection murmur heard loudest over the right
upper sternal border which did not radiate. Her breath
sounds were absent at the bases and diminished 2/3 of the
way up the posterior lung fields. She had 2+ pitting edema
to the hips. There was no hepatomegaly or macroglossia.
Her electrocardiogram (ECG) at the time of admission
showed diffuse low voltage and Q waves in leads III and
aVf (Figure 1). A trans-thoracic echocardiogram (TTE) was
performed soon after admission (Figure 2). It showed
moderately reduced left ventricular function with an ejec-
tion fraction (EF) of 33%, a small left ventricular cavity
(20.4 cm2  in diastole, 16.3 cm2  in systole), markedly
increased wall thickness (septal diameter in diastole =
1.86 cm), and severe concentric hypertrophy. Addition-
ally, there was moderate mitral regurgitation. A speckled
pattern in the myocardium was noted.
Both serum and urine protein electrophoresis demon-
strated a normal protein distribution without a mono-
clonal spike. She had modestly impaired renal function
(estimated GFR 51 mL/min by Cockocroft-Gault, 52 mL/
min by Modification of Diet in Renal Disease Criteria)
with no proteinuria.
She was diuresed using furosemide, and treated with
monopril, metoprolol (later changed to carvedilol for bet-
ter blood pressure control), and digoxin. There was little
subjective or objective improvement in her condition
with this treatment. The digoxin was stopped on the 5th
hospital day, as the suspicion for Amyloidosis at that
point in time was high.
She underwent a fat pad aspiration biopsy, which was
negative for amyloid by Congo Red Staining. At that time,
it was felt that her refractory condition, in combination
with the ECG and TTE data was sufficiently suggestive of
amyloid disease that she should undergo endomyocardial
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biopsy as a means of definitive diagnosis. The biopsy
revealed AL Amyloidosis with kappa and lambda light
chain deposits. Stains for iron and amyloid AA were neg-
ative.
Discussion
On further review, it was felt that the presentation was not
particularly consistent with AL Amyloidosis given her
demographics and the absence of other organ involve-
ment or an elevated Ig fraction, and so the biopsy was sent
for further analysis of transthyretin deposition. The results
of that test were positive. Given the demographics and
pertinent findings, it was concluded that the AL Amy-
loidosis finding was a false positive, and that the patient
in reality had ATTR amyloidosis. Unfortunately, the
patient had returned to Jamaica and was lost to follow-up
before the correct diagnosis was made.
Conclusion
Lab error with respect to differentiating Primary (AL) from
Familial (ATTR) amyloidosis is uncommon, but not
unheard of [2,11]. The largest series addressing Familial
Amyloidosis noted a very low frequency of transthyretin
amyloid samples cross reacting with light chain staining.
The incidence was one in 50 samples - the one sample
"presumably reflecting nonspecific binding due to varia-
bility in tissue processing" [2]. Lachmann et al [9] evalu-
ated 350 cases of "AL" Amyloidosis in a British cohort, of
which nearly 10% had been misdiagnosed. Thirteen of
those cases (4%) were determined to be ATTR Amyloid
using genetic analysis; 3 of those as a result of the Ile 122
variant.
This case was meaningful in that it highlights the impor-
tance of recognizing the disparate clinical characteristics
of the various types of Amyloidosis. Further, it emphasizes
the high level of suspicion needed to make a proper diag-
nosis. Given the rarity of the disease, many practitioners
are not necessarily well aware of the differences. However,
the distinction is critical. The prognosis varies signifi-
cantly, along with the potential treatment strategy (chem-
otherapy for AL amyloid, liver transplant or possibly Non-
Steroidal Anti-Inflammatory Drugs for ATTR). Further, the
ability to anticipate disease in family members of ATTR
Amyloid patients could help reduce the burden of this fre-
quently terminal disease. Clinician awareness of the vari-
ous forms of Amyloidosis and the potential for lab error is
key to ensuring an accurate diagnosis and timely interven-
tion.
Consent
Multiple attempts were made to contact the patient
regarding her condition, as well as to obtain consent for
this case report. Unfortunately, she was only transiently in
the U.S., and no forwarding information was left on her
departure. Attempts to contact her family have been
unsuccessful. After reading through the provisions in your
instructions in the case where consent is unobtainable, I
believe all three of the following conditions have been
met:
• all reasonable attempts to gain consent have been
made
￿ the patient is anonymous
￿ there is no reason to think that the patient or their
family would object to publication
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An Echocardiogram shows dramatic left ventricular hyper- trophy (arrows) and a small ventricular cavity Figure 2
An Echocardiogram shows dramatic left ventricular 
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